Guardant Health Inc (NASDAQ:GH) major shareholder Vision Fund (Aiv M1) Softbank purchased 2,033,990 shares of the company’s stock in a transaction that occurred on Tuesday, March 12th. The shares were acquired at an average price of $9.83 per share, for a total transaction of $19,994,121.70. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Major shareholders that own more than 10% of a company’s shares are required to disclose their sales and purchases with the SEC.
Shares of GH stock traded up $3.06 during trading on Thursday, reaching $97.51. 2,098,060 shares of the company’s stock traded hands, compared to its average volume of 558,957. The stock has a market capitalization of $6.35 billion and a P/E ratio of -34.83. Guardant Health Inc has a 1 year low of $27.04 and a 1 year high of $100.74.
Guardant Health (NASDAQ:GH) last announced its quarterly earnings results on Tuesday, March 12th. The company reported ($0.30) EPS for the quarter, beating the Zacks’ consensus estimate of ($0.35) by $0.05. The business had revenue of $32.87 million for the quarter, compared to analysts’ expectations of $24.57 million. On average, sell-side analysts anticipate that Guardant Health Inc will post -1.26 EPS for the current fiscal year.
A number of analysts recently commented on the stock. William Blair restated an “outperform” rating on shares of Guardant Health in a research note on Wednesday. JPMorgan Chase & Co. upped their price target on shares of Guardant Health from $42.00 to $85.00 and gave the company an “overweight” rating in a research note on Wednesday. Finally, Bank of America restated a “neutral” rating and set a $60.00 price target (up from $42.00) on shares of Guardant Health in a research note on Thursday, February 28th. One equities research analyst has rated the stock with a hold rating and four have assigned a buy rating to the company’s stock. The company presently has an average rating of “Buy” and a consensus target price of $72.50.
A number of institutional investors have recently bought and sold shares of the stock. Temasek Holdings Private Ltd bought a new stake in Guardant Health during the 4th quarter worth approximately $60,633,000. Orbimed Advisors LLC bought a new stake in Guardant Health during the 4th quarter worth approximately $57,681,000. BlackRock Inc. bought a new stake in Guardant Health during the 4th quarter worth approximately $41,894,000. Jennison Associates LLC bought a new stake in Guardant Health during the 4th quarter worth approximately $31,700,000. Finally, Lord Abbett & CO. LLC bought a new stake in Guardant Health during the 4th quarter worth approximately $20,024,000. 69.54% of the stock is currently owned by institutional investors and hedge funds.
WARNING: This piece of content was first posted by Zolmax and is owned by of Zolmax. If you are reading this piece of content on another site, it was illegally stolen and reposted in violation of U.S. & international copyright & trademark legislation. The legal version of this piece of content can be viewed at https://zolmax.com/investing/vision-fund-aiv-m1-softbank-buys-2033990-shares-of-guardant-health-inc-gh-stock/2963122.html.
Guardant Health Company Profile
Guardant Health, Inc, a precision oncology company, provides non-invasive cancer diagnostics. It offers liquid biopsy tests for advanced stage cancer, such as Guardant360, a molecular diagnostic test that measures various cancer-related genes from circulating tumor DNA (ctDNA); and GuardantOMNI, a broader panel measuring various genes from ctDNA.
Recommended Story: Bid-Ask Spread
Receive News & Ratings for Guardant Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Guardant Health and related companies with MarketBeat.com's FREE daily email newsletter.